239 related articles for article (PubMed ID: 36165723)
21. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
Salgia R
Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
[TBL] [Abstract][Full Text] [Related]
22. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of FGFR1 expression and amplification in patients with HNSCC: A systematic review and meta-analysis.
Hu Y; Ai LS; Zhou LQ
PLoS One; 2021; 16(5):e0251202. PubMed ID: 33989301
[TBL] [Abstract][Full Text] [Related]
24. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1.
Nguyen PT; Tsunematsu T; Yanagisawa S; Kudo Y; Miyauchi M; Kamata N; Takata T
Br J Cancer; 2013 Oct; 109(8):2248-58. PubMed ID: 24045665
[TBL] [Abstract][Full Text] [Related]
25. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.
Aytatli A; Barlak N; Sanli F; Caglar HO; Gundogdu B; Tatar A; Ittmann M; Karatas OF
Cell Oncol (Dordr); 2022 Feb; 45(1):41-56. PubMed ID: 34837170
[TBL] [Abstract][Full Text] [Related]
26. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.
Gyanchandani R; Ortega Alves MV; Myers JN; Kim S
Mol Cancer Res; 2013 Dec; 11(12):1585-96. PubMed ID: 24092775
[TBL] [Abstract][Full Text] [Related]
27. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
28. Expression of fibroblast growth factor binding protein in head and neck cancer.
Li W; Wang C; Juhn SK; Ondrey FG; Lin J
Arch Otolaryngol Head Neck Surg; 2009 Sep; 135(9):896-901. PubMed ID: 19770422
[TBL] [Abstract][Full Text] [Related]
29. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.
Singleton KR; Kim J; Hinz TK; Marek LA; Casás-Selves M; Hatheway C; Tan AC; DeGregori J; Heasley LE
Mol Pharmacol; 2013 Apr; 83(4):882-93. PubMed ID: 23371912
[TBL] [Abstract][Full Text] [Related]
30. Molecular genetics of head and neck squamous cell carcinoma.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):131-137. PubMed ID: 30893149
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
32. Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma.
Wang CY; Foy JJ; Siewert TY; Haraf DJ; Ginat DT
J Comput Assist Tomogr; 2020; 44(4):546-552. PubMed ID: 32697524
[TBL] [Abstract][Full Text] [Related]
33. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
34. Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC; Ronca R; Presta M; Giacomini A
Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
[TBL] [Abstract][Full Text] [Related]
35. SEC61G overexpression and DNA amplification correlates with prognosis and immune cell infiltration in head and neck squamous cell carcinoma.
Lu T; Chen Y; Gong X; Guo Q; Lin C; Luo Q; Tu Z; Pan J; Li J
Cancer Med; 2021 Nov; 10(21):7847-7862. PubMed ID: 34590792
[TBL] [Abstract][Full Text] [Related]
36. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
37. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
39. Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling.
Lakshmanachetty S; Balaiya V; High WA; Koster MI
Mol Cancer Res; 2019 Jun; 17(6):1279-1293. PubMed ID: 30910837
[TBL] [Abstract][Full Text] [Related]
40. The Proteomic Landscape of Growth Factor Signaling Networks Associated with
Chen Z; Zhang C; Chen J; Wang D; Tu J; Van Waes C; Saba NF; Chen ZG; Chen Z
Cancer Res; 2021 Sep; 81(17):4402-4416. PubMed ID: 34167951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
